title: Changes in immunological recovery in patients who received post-transplant G-CSF or GM-CSF after autologous peripheral blood stem cell transplantation (PBSCT).
abstract: In this prospective study, the effects of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on immunological reconstitution after autologous peripheral blood stem cell transplantation (PBSCT) were investigated for 6 months. Thirty-five patients received G-CSF 5 microg/kg per day and 26 patients received GM-CSF SC 5 microg/kg per day from day 1 to leukocyte engraftment (>1000 per mm3). Peripheral blood samples were obtained on 14, 28, 100, and 180 days after transplantation for immunological evaluation. CD3+, CD4+, CD8+, CD19+, and CD56+ cells were analysed by flow cytometry. Immunoglobulin levels (IgG, IgA, and IgM) and complement levels (C3c and C4) were measured by nephelometry. Both G-CSF and GM-CSF groups were comparable with respect to age, sex, the period from diagnosis to transplantation, total nucleated cells infused, the number of CD34+ cells, conditioning regimens (TBI and non-TBI), and post-transplant infection. CD3+ and CD8+ cells on day 14 following autologous PBSCT + G-CSF were significantly higher than following autologous PBSCT + GM-CSF (p = 0.008 and p = 0.021, respectively). The number of CD4 cells and the CD4/CD8 ratio were not different at several time points between the two groups. CD19+, CD56+ cells and immunoglobulin levels showed a faster recovery pattern in the autologous PBSCT + G-CSF group. The effect of G-CSF on immune reconstitution after autologous PBSCT is more prominent than that of GM-CSF. The possible role of haematopoietic growth factor on immune recovery and its clinical importance should be investigated in further studies.
authors.affiliation: Gulhane School of Medicine BMT Center, Etlik-Ankara, Turkey. onkoloji@obs.gata.edu.tr
authors.forename: F
authors.initials: F
authors.lastname: Arpaci
authors.forename: T
authors.initials: T
authors.lastname: Dogru
authors.forename: B
authors.initials: B
authors.lastname: Ozturk
authors.forename: S
authors.initials: S
authors.lastname: Komurcu
authors.forename: A
authors.initials: A
authors.lastname: Ozet
authors.forename: M I
authors.initials: MI
authors.lastname: Yilmaz
authors.forename: M
authors.initials: M
authors.lastname: Beyzadeoglu
authors.forename: M
authors.initials: M
authors.lastname: Turan
authors.forename: A
authors.initials: A
authors.lastname: Sengul
authors.forename: A
authors.initials: A
authors.lastname: Yalcin
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007107:Immune System / Q000187:drug effects* / Q000254:growth & development; D007132:Immunoglobulin Isotypes / Q000032:analysis; D007700:Kinetics; D018655:Lymphocyte Count; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous
chemical_list: D015703:Antigens, CD; D007132:Immunoglobulin Isotypes; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor